Quick Answer
Decoy Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $10.71 million for the year ending 2025.
- Decoy Therapeutics Inc. showed an increase of +339.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Decoy Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $7.30 million | Q2 2019: $6.51 million | Q3 2019: $4.00 million | Q2 2020: $7.22 million | Q3 2020: $9.56 million | Q1 2021: $36.61 million | Q2 2021: $33.08 million | Q3 2021: $31.90 million | Q1 2022: $24.19 million | Q2 2022: $22.65 million | Q3 2022: $16.82 million | Q1 2023: $9.27 million | Q2 2023: $11.54 million | Q3 2023: $7.58 million | Q1 2024: $4.37 million | Q2 2024: $3.27 million | Q3 2024: $3.28 million | Q1 2025: $1.80 million | Q2 2025: $794.9 thousand | Q3 2025: $4.81 million.
- Over the full 9 years of available data (2017 to 2025), Decoy Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 44.2%.
- Historical annual values: Fiscal year 2025: $10.71 million | Fiscal year 2024: $2.43 million | Fiscal year 2023: $5.90 million | Fiscal year 2022: $12.11 million | Fiscal year 2021: $29.21 million | Fiscal year 2020: $11.12 million | Fiscal year 2019: $3.74 million | Fiscal year 2018: $3.23 million | Fiscal year 2017: $19.19 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: